NCT02762084 2020-07-23
Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients
PellePharm, Inc.
Phase 2 Completed
PellePharm, Inc.
Weill Medical College of Cornell University
The University of Texas Health Science Center at San Antonio
PellePharm, Inc.
University of Alabama at Birmingham